Chapter 7 Trustee filed a motion for sale of substantially all of the assets of Diadexus, Inc. in the US Bankruptcy on July 7, 2016. The Trustee seeks to sell estate's right, title, and interest in and to the Debtor's operational assets to Cleveland HeartLab, Inc. for a purchase price of $6.69 million in the form of credit bid and $0.34 million of cash plus assumption of assumed liabilities. The $338,000 cash portion of the consideration includes a $0.33 million carve out for the bankruptcy estate, $10,000 for the expenses related to noticing the sale motion for hearing, and $3,000 to MyCircleHealth as reimbursement for its post-petition payments to the liquid nitrogen supplier. The buyer is entitled for bid protections include a break-up fee equal to 2% of the Purchase Price i.e. $0.14 million and reimbursement of Buyer’s reasonable fees and out-of-pocket expenses in connection with the contemplated transaction, not to exceed $0.1 million. The sale is subject to overbid. The minimum initial overbid amount is $7.2 million, plus the over bidder’s agreement conditions. The subsequent bids will be in increments of $0.05 million each. All interested bidder must deposit the good faith deposit of $0.36 million. The auction shall be held on July 13, 2016. The Trustee will file the definitive executed Sale Agreement with the Bankruptcy Court prior to the July 13, 2016 hearing. Cooley LLP acted as advisor to buyer.